Latest News
Conference Coverage
Acupuncture significantly reduces AI-associated arthralgias
SAN ANTONIO – Women receiving acupuncture had significantly lower joint pain scores in a randomized phase 3 trial.
Conference Coverage
Acute kidney injury linked with doubled inpatient VTEs
TORONTO – Which comes first: the acute kidney injury or the venous thromboembolism?
Conference Coverage
No evidence for perioperative AI benefit in early ER/PR+ breast cancer
SAN ANTONIO – Among nearly 4,500 women enrolled in the POETIC Trial, TTR and OS were similar whether patients received AI therapy or not.
Conference Coverage
Dose intensification gets more mileage out of adjuvant chemo
SAN ANTONIO – Women were less likely to experience recurrence or die of breast cancer if they were given dose-intensified chemotherapy.
Conference Coverage
Ribociclib plus standard of care improves PFS in premenopausal HR+/HER2-negative breast cancer
SAN ANTONIO – The median PFS for women treated with ribociclib plus endocrine therapy was 23.8 months, vs. 13 months for women treated with the...
Feature
MedPAC: Ditch meaningful use, patient measures under MIPS
WASHINGTON – Population-level outcomes measures are the key focus of a proposed program to replace Medicare’s new MIPS program.
Conference Coverage
VIDEO: Dr. Matteo Lambertini answers questions on temporary ovarian suppression
SAN ANTONIO – Temporarily suppressing ovarian function with a gonadotropin-releasing hormone analog during chemotherapy helps preserve fertility...
Conference Coverage
Novel ADC shows promise in metastatic triple-negative breast cancer
SAN ANTONIO – Overall response rate was 34% with sacituzumab govitecan as a single agent among heavily pretreated patients with metastatic TNBC....
From the Journals
Parents taking photos of kids’ lesions for telederm diagnosis looks promising
Concordance of teledermatology and in-person diagnoses was high.
Conference Coverage
VIDEO: Good responses with antibody-drug conjugate in third-line metastatic TNBC therapy
SAN ANTONIO - Dr. Aditya Bardia discusses the 34% overall response rate and describes planned clinical trials pitting the ADC against standard of...
From the Journals
Pharmacomechanical thrombolysis does not reduce post-thrombotic syndrome risk
The ATTRACT trial results contrast with recent reports from another randomized trial, known as CAVENT.